-- Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Posts Q4 Revenue $75.7M
8:17AM ET 3/09/2022 MT Newswires...
Quotes Snapshot > LJPC
La Jolla Pharmaceutical Co LJPC:NASDAQ
Last Price$4.01NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
Today's Change+0.04(1.01%)
Bid (Size)$3.75 (2)
Ask (Size)$4.60 (7)
Day Low / High$4.01 - 4.23
Volume44.6 K
Read more news Recent News
Insider Sell: La Jolla Pharmaceutical
6:22AM ET 12/02/2021 MT NewswiresKevin C Tang, 10% Owner, Director, on November 29, 2021, sold 441,290 shares in La Jolla Pharmaceutical (LJPC) for $1,734,150. Following the Form 4 filing...
La Jolla Pharmaceutical Launches $10 Million Share Buyback Plan
11:12AM ET 11/17/2021 MT NewswiresLa Jolla Pharmaceutical (LJPC) said Wednesday it has launched a share buyback program of up to $10 million. Repurchases can be made from time to time and...
-- Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Posts Q3 Revenue $13.3M
8:51AM ET 11/04/2021 MT Newswires...
View all Commentary and Analysis
Marinus Pharmaceuticals (MRNS) Reports Q1 Loss, Tops Revenue Estimates
4:35PM ET 5/12/2022 ZacksMarinus Pharmaceuticals (MRNS) delivered earnings and revenue surprises of 40.23% and 548.36%,...
Our Take On La Jolla Pharmaceutical Company
2:06PM ET 7/02/2021 Seeking AlphaCompany Profile
Business DescriptionLa Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. View company web site for more details
| Address | 201 Jones Road Waltham, Massachusetts 02451 |
| Phone | +1.617.715.3600 |
| Number of Employees | 169 |
| Recent SEC Filing | 05/03/2022 4 |
| President, Chief Executive Officer & Director | Larry G. Edwards |
| Senior Vice President-Pharmaceutical Operations | Luke Seikkula |
| Chief Financial Officer & Secretary | Michael S. Hearne |
| Chief Medical Officer | Tony Hodges |
Company Highlights
| Price Open | $4.05 |
| Previous Close | $4.01 |
| 52 Week Range | $3.35 - 5.69 |
| Market Capitalization | $102.7 M |
| Shares Outstanding | 25.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 05/13/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 7.04 |
| Earnings per Share | $0.56 |
| Beta vs. S&P 500 | N/A |
| Revenue | $10.1 M |
| Net Profit Margin | 25.96% |
| Return on Equity | -28.61% |
Analyst Ratings as of 03/11/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |